Lilly To Focus Mainly On Pipeline Development As It Faces Steep Patent Cliff
This article was originally published in The Pink Sheet Daily
Executive Summary
With generic competition around the corner for blockbusters like Zyprexa, Lilly can't count on many more quarters like the past one's 16 percent net income growth.